We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
- Authors
Jing Zhang; Zi Bo Han; Yu Liang; Xue Feng Zhang; Yu Qin Jin; Li Fang Du; Shuai Shao; Hui Wang; Jun Wei Hou; Ke Xu; Wenwen Lei; Ze Hua Lei; Zhao Ming Liu; Jin Zhang; Ya Nan Hou; Ning Liu; Fu Jie Shen; Jin Juan Wu; Xiang Zheng; Xin Yu Li
- Abstract
Large-scale populations in the world have been vaccinated with COVID-19 vaccines, however, breakthrough infections of SARS-CoV-2 are still growing rapidly due to the emergence of immune-evasive variants, especially Omicron. It is urgent to develop effective broad-spectrum vaccines to better control the pandemic of these variants. Here, we present a mosaic-type trimeric form of spike receptor-binding domain (mos-tri-RBD) as a broad-spectrum vaccine candidate, which carries the key mutations from Omicron and other circulating variants. Tests in rats showed that the designed mos-tri-RBD, whether used alone or as a booster shot, elicited potent cross-neutralizing antibodies against not only Omicron but also other immune-evasive variants. Neutralizing antibody ID50 titers induced by mos-tri-RBD were substantially higher than those elicited by homo-tri-RBD (containing homologous RBDs from prototype strain) or the BIBP inactivated COVID-19 vaccine (BBIBP-CorV). Our study indicates that mos-tri-RBD is highly immunogenic, which may serve as a broad-spectrum vaccine candidate in combating SARS-CoV-2 variants including Omicron.
- Subjects
SARS-CoV-2 Omicron variant; COVID-19 vaccines; AVIAN influenza; BREAKTHROUGH infections; ANTIBODY titer; IMMUNOGLOBULINS; VACCINE effectiveness
- Publication
eLife, 2022, p1
- ISSN
2050-084X
- Publication type
Article
- DOI
10.7554/eLife.78633